Charles Schwab Investment Management Inc. Sells 30,332 Shares of Metagenomi, Inc. (NASDAQ:MGX)

Charles Schwab Investment Management Inc. cut its position in shares of Metagenomi, Inc. (NASDAQ:MGX) by 67.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 14,779 shares of the company’s stock after selling 30,332 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Metagenomi were worth $32,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Novo Holdings A S grew its holdings in shares of Metagenomi by 3.5% in the 2nd quarter. Novo Holdings A S now owns 1,800,000 shares of the company’s stock valued at $7,344,000 after acquiring an additional 60,825 shares in the last quarter. Green Alpha Advisors LLC bought a new position in Metagenomi in the third quarter valued at approximately $69,000. Resolute Advisors LLC increased its position in shares of Metagenomi by 165.0% during the 2nd quarter. Resolute Advisors LLC now owns 26,500 shares of the company’s stock worth $108,000 after purchasing an additional 16,500 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Metagenomi during the 2nd quarter worth approximately $66,000. Finally, Rhumbline Advisers acquired a new stake in shares of Metagenomi in the 2nd quarter valued at approximately $26,000.

Metagenomi Trading Up 4.9 %

NASDAQ:MGX opened at $4.05 on Friday. The firm’s fifty day moving average price is $2.31 and its two-hundred day moving average price is $3.18. Metagenomi, Inc. has a one year low of $1.61 and a one year high of $12.74.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Chardan Capital restated a “buy” rating and set a $15.00 target price on shares of Metagenomi in a report on Wednesday, November 20th. HC Wainwright lifted their price objective on shares of Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Metagenomi presently has a consensus rating of “Moderate Buy” and an average target price of $16.67.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.